Massive liver cancer study aims to personalize treatment for 2000 patients
NCT ID NCT07156617
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will analyze data from 2000 liver cancer patients to see how well interventional therapy combined with systemic drugs (like targeted therapy and immunotherapy) works in real life. Researchers will look at differences in outcomes and side effects, and use machine learning to predict risks. The goal is to help doctors tailor treatments to each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Interventional therapy (procedure) and systemic therapy (drugs like Lenvatinib, Apatinib, Camrelizumab, Tislelizumab)
What this could lead to
If successful, this could help doctors personalize liver cancer treatment by identifying which patients benefit most from combined therapy and predicting side effects.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary across patients and may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deng zhou People's Hospital
Dengzhou, Henan, China
Contact
-
First People's Hospital of Shangqiu
Shangqiu, Henan, China
Contact
-
Huai He Hospital of Henan University
Kaifeng, Henan, China
Contact
-
Jiangxi Provincial People's Hospitail
Nanchang, Jiangxi, China
Contact
-
Luo Yang Central Hospital
Luoyang, Henan, China
Contact
-
Second People's Hospital of Jiaozuo
Jiaozuo, China
Contact
-
The First Affiliated Hospital of Henan University of science and Technology
Luoyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Hainan Medical Universsity
Haikou, Hainan, China
Contact
-
The Second People's Hospital of Jiaozuo
Jiaozuo, Henan, China
Contact
-
Wuxi No.5 People's Hospital
Wuxi, Jiangsu, China
-
Xingtai No.5 Hospital
Xingtai, Hebei, China
Contact
-
Zhou Kou Central Hospital
Zhoukou, Henan, China
Contact